Evidence map›Paper›PMID 35668443›Full record

ArticleJournal of ovarian research2022

Prohibitin 1 interacts with p53 in the regulation of mitochondrial dynamics and chemoresistance in gynecologic cancers.

Bao Kong, Chae Young Han, Se Ik Kim, David A Patten, Youngjin Han, Euridice Carmona, Dar-Bin Shieh, Annie C Cheung, Anne-Marie Mes-Masson, Mary-Ellen Harper and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal of ovarian research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Mitochondrial metabolism and cancer therapeutic innovation.Signal transduction and targeted therapy · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Prohibitin 1 inhibits cell proliferation and induces apoptosisWorld journal of gastrointestinal oncology · 2024
    Article
  12. Prohibitions in the meta-inflammatory response: a review.Frontiers in molecular biosciences · 2024
    Review
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 5 countries.

Bao Kong *Departments of Obstetrics and Gynecology and Cellular and Molecular Medicine, Interdisciplinary School of Health Sciences University of Ottawa, and Chronic Disease Program, Ottawa Hospital Research Institute, 501 Smyth Road, Mail Box #511, ON, K1H 8L6, Ottawa, Canada.
Chae Young Han *Departments of Obstetrics and Gynecology and Cellular and Molecular Medicine, Interdisciplinary School of Health Sciences University of Ottawa, and Chronic Disease Program, Ottawa Hospital Research Institute, 501 Smyth Road, Mail Box #511, ON, K1H 8L6, Ottawa, Canada.
Se Ik KimDepartment of Obstetrics and Gynecology and Cancer Research Institute, Seoul National University College of Medicine, Seoul, 03080, Republic of Korea.
David A PattenDepartment of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Canada.
Youngjin HanDepartment of Obstetrics and Gynecology and Cancer Research Institute, Seoul National University College of Medicine, Seoul, 03080, Republic of Korea.
Euridice CarmonaCentre de recherche du Centre hospitalier de l'Université de Montréal and Institut du cancer de Montréal, Montréal, Canada.
Dar-Bin ShiehInstitute of Basic Medical Science, Institute of Oral Medicine and Department of Stomatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, 704, Taiwan.
Annie C CheungDepartment of Pathology, The University of Hong Kong, Hong Kong, SAR, China.
Anne-Marie Mes-MassonCentre de recherche du Centre hospitalier de l'Université de Montréal and Institut du cancer de Montréal, Montréal, Canada.
Mary-Ellen HarperDepartment of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Canada.
Yong Sang SongDepartment of Obstetrics and Gynecology and Cancer Research Institute, Seoul National University College of Medicine, Seoul, 03080, Republic of Korea.
Benjamin K TsangDepartments of Obstetrics and Gynecology and Cellular and Molecular Medicine, Interdisciplinary School of Health Sciences University of Ottawa, and Chronic Disease Program, Ottawa Hospital Research Institute, 501 Smyth Road, Mail Box #511, ON, K1H 8L6, Ottawa, Canada. btsang@ohri.ca.
University of Ottawa · CASeoul National University · KRCentre Hospitalier de l’Université de Montréal · CAChinese University of Hong Kong · CNNational Cheng Kung University Hospital · TWOttawa Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMitochondrial dynamics (e.g. fission/fusion) play an important role in controlling chemoresistance in representative gynecologic malignancies, ovarian and cervical cancer. Processing the long form of Optic atrophy (L-Opa)1 is a distinctive character of mitochondrial fragmentation, associated with chemosensitivity. Here, we examined the role of prohibitin (Phb)1 in increasing L-Opa1 processing via the regulating mitochondrial protease, Oma1 and its direct interaction with p-p53 (ser15) and pro-apoptotic Bcl-2 antagonist/killer (Bak) 1 in the signaling axis and if this phenomenon is associated with prognosis of patients.

methodsWe compared Cisplatin (CDDP)-induced response of mitochondrial dynamics, molecular interaction among p-p53 (ser15)-Phb1-Bak, and chemoresponsiveness in paired chemosensitive and chemoresistant gynecologic cancer cells (ovarian and cervical cancer cell lines) using western blot, immunoprecipitation, sea horse, and immunofluorescence. Translational strategy with proximity ligation assessment in phb1-p-p53 (ser15) in human ovarian tumor sections further confirmed in vitro finding, associated with clinical outcome.

resultsWe report that: (1) Knock-down of Phb1 prevents Cisplatin (cis-diamine-dichloroplatinum; CDDP) -induced changes in mitochondrial fragmentation and Oma1 mediated cleavage, and Opa1 processing; (2) In response to CDDP, Phb1 facilitates the p-p53 (ser15)-Phb1-Bak interaction in mitochondria in chemosensitive gynecologic cancer cells but not in chemoresistant cells; (3) Akt overexpression results in suppressed p-p53(Ser15)-Phb1 interaction and dysregulated mitochondrial dynamics, and (4) Consistent with in vitro findings, proximity ligation assessment (PLA) in human ovarian tumor sections demonstrated that p-p53(ser15)-Phb1-Bak interaction in mitochondria is associated with better chemoresponsiveness and clinical outcome of patients. Determining the molecular mechanisms by which Phb1 facilitates mitochondrial fragmentation and interacts with p53 may advance the current understanding of chemoresistance and pathogenesis of gynecologic cancer.

conclusionDetermining the key molecular mechanisms by which Phb1 facilitates the formation of p-p53 (ser15)-Bak-Phb1 and its involvement in the regulation of mitochondrial dynamics and apoptosis may ultimately contribute to the current understanding of molecular and cellular basis of chemoresistance in this gynecologic cancer.

Indexed as

Antineoplastic AgentsGenital Neoplasms, FemaleOvarian NeoplasmsUterine Cervical NeoplasmsApoptosisCell Line, TumorCisplatinDrug Resistance, NeoplasmFemaleHumansMitochondrial DynamicsProhibitinsTumor Suppressor Protein p53Antineoplastic AgentsCisplatinProhibitinsTumor Suppressor Protein p53BakCDDPChemoresistanceMitochondrial fragmentationp53Phb1

Identifiers

PMID35668443
PMCPMC9172162
OpenAlexW4281777985

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.